ADA 2018 Outstanding Achievement in Clinical Diabetes Research Award
Prof Rury Holman is the recipient of the 2018 Outstanding Achievement in Clinical Diabetes Research Award by the American Diabetes Association. This award recognizes exceptional contributions in patient-oriented or clinical outcomes research that have had a significant impact on diabetes prevention and treatment....
Exploring the impact of Diabetes UK research
Diabetes UK have released their first ever Research Impact Report which explores the impact of Diabetes UK research over the last 80 years. It was launched at a reception held on Thursday 15th March 2018 at the Diabetes UK Professional Conference....
Dr. M. Angelyn Bethel leaves the Diabetes Trials Unit
After 10 years at the Diabetes Trials Unit (DTU), Dr. Angelyn Bethel is leaving to pursue career opportunities in the pharmaceutical industry.
Dr. Bethel has the following message for her friends and co-workers: “My decision to leave the DTU was not taken lightly....
DTU Director discusses EXSCEL
The Exenatide Study of Cardiovascular Event Lowering (EXSCEL) is a trial that assessed the long-term cardiovascular safety and efficacy of once-weekly exenatide, administered in patients with type 2 diabetes who had a wide range of cardiovascular risk. In this video, Professor Rury Holman shares his insights into the trial results.
ACP Journal Club review of EXSCEL
The ACP Journal Club has identified EXCSEL as an original study that warrants immediate attention by physicians attempting to keep pace with important advances in internal medicine.
[Click here to see review